NI201200027A - Anticuerpos contra el exto - Google Patents
Anticuerpos contra el extoInfo
- Publication number
- NI201200027A NI201200027A NI201200027A NI201200027A NI201200027A NI 201200027 A NI201200027 A NI 201200027A NI 201200027 A NI201200027 A NI 201200027A NI 201200027 A NI201200027 A NI 201200027A NI 201200027 A NI201200027 A NI 201200027A
- Authority
- NI
- Nicaragua
- Prior art keywords
- erbb3
- antibodies
- antigen
- receptor
- binding fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23579909P | 2009-08-21 | 2009-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201200027A true NI201200027A (es) | 2013-01-29 |
Family
ID=43607614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201200027A NI201200027A (es) | 2009-08-21 | 2012-02-15 | Anticuerpos contra el exto |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP2467164A2 (enExample) |
| JP (1) | JP5752687B2 (enExample) |
| KR (1) | KR20120059568A (enExample) |
| CN (1) | CN103002912A (enExample) |
| AU (1) | AU2010284018C1 (enExample) |
| BR (1) | BR112012003809A2 (enExample) |
| CA (1) | CA2771744A1 (enExample) |
| CR (1) | CR20120108A (enExample) |
| DO (1) | DOP2012000044A (enExample) |
| EA (1) | EA201200195A1 (enExample) |
| EC (1) | ECSP12011740A (enExample) |
| IL (1) | IL218097A0 (enExample) |
| IN (1) | IN2012DN01518A (enExample) |
| MA (1) | MA33582B1 (enExample) |
| MX (1) | MX336091B (enExample) |
| NI (1) | NI201200027A (enExample) |
| PE (1) | PE20121585A1 (enExample) |
| SG (1) | SG178509A1 (enExample) |
| TN (1) | TN2012000057A1 (enExample) |
| WO (1) | WO2011022727A2 (enExample) |
| ZA (1) | ZA201201195B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ579644A (en) | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| KR101806323B1 (ko) | 2009-11-13 | 2017-12-07 | 다이이치 산쿄 유럽 게엠베하 | Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법 |
| PH12012501157A1 (en) | 2009-12-22 | 2012-10-29 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| KR101764453B1 (ko) | 2010-04-09 | 2017-08-02 | 아베오 파마슈티컬즈, 인크. | 항-erbb3 항체 |
| ME02637B (me) | 2010-08-20 | 2017-06-20 | Novartis Ag | Antitela za receptor 3 faktora rasta epiderma (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| IT1402149B1 (it) * | 2010-10-04 | 2013-08-28 | Ist Fisioterap Ospitalroma | Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2. |
| WO2012059857A2 (en) | 2010-11-01 | 2012-05-10 | Symphogen A/S | Pan-her antibody composition |
| MX336197B (es) * | 2011-04-19 | 2016-01-11 | Merrimack Pharmaceuticals Inc | Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos. |
| WO2012176779A1 (ja) * | 2011-06-20 | 2012-12-27 | 協和発酵キリン株式会社 | 抗ｅｒｂＢ３抗体 |
| WO2013048883A2 (en) | 2011-09-30 | 2013-04-04 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| EP2764364B1 (en) | 2011-10-06 | 2021-08-18 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-erbb3 antibodies |
| WO2013071058A1 (en) * | 2011-11-09 | 2013-05-16 | The Uab Research Foundation | Her3 antibodies and uses thereof |
| CN108341873B (zh) | 2011-12-05 | 2022-03-25 | 诺华股份有限公司 | 表皮生长因子受体3(her3)的抗体 |
| US20150037336A1 (en) * | 2012-02-22 | 2015-02-05 | U3 Pharma Gmbh | Combination of hb-egf binding protein and egfr inhibitor |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| US20160232293A1 (en) * | 2013-10-17 | 2016-08-11 | Sanford-Burnham Medical Research Institute | Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| CA2941030C (en) | 2014-02-28 | 2025-05-13 | Merus N.V. | ANTIBODIES THAT BIND TO EGFR AND ERBB3 |
| CN105367657B (zh) * | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
| WO2016038610A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| JP7296728B2 (ja) | 2015-10-23 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 癌の成長を抑制する結合分子 |
| JP7737220B2 (ja) | 2017-03-31 | 2025-09-10 | メルス ナムローゼ フェンノートシャップ | ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体 |
| EP3625264B9 (en) | 2017-05-17 | 2023-10-25 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
| US11390686B2 (en) | 2017-08-09 | 2022-07-19 | University Of Saskatchewan | HER3 binding agents and uses thereof |
| RS66708B9 (sr) | 2017-08-09 | 2025-08-29 | Merus Nv | Antitela koja se vezuju za egfr i cmet |
| GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
| WO2019241893A2 (en) * | 2018-06-22 | 2019-12-26 | Crd Pharmaceuticals Inc | Anti-her3 antibody and uses thereof |
| CN116133694B (zh) * | 2020-10-14 | 2026-03-06 | 苏州盛迪亚生物医药有限公司 | 抗her3抗体和抗her3抗体药物偶联物及其医药用途 |
| EP4247430A4 (en) * | 2020-11-20 | 2024-12-11 | Actinium Pharmaceuticals, Inc. | Her3 radioimmunotherapy for the treatment of solid cancers |
| EP4355787A4 (en) * | 2021-06-15 | 2025-04-30 | Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. | Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof |
| WO2023198138A1 (zh) * | 2022-04-13 | 2023-10-19 | 上海翰森生物医药科技有限公司 | 抗体或其抗原结合片段及其医药用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ579644A (en) * | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
-
2010
- 2010-08-23 AU AU2010284018A patent/AU2010284018C1/en not_active Ceased
- 2010-08-23 CA CA2771744A patent/CA2771744A1/en not_active Abandoned
- 2010-08-23 WO PCT/US2010/046364 patent/WO2011022727A2/en not_active Ceased
- 2010-08-23 PE PE2012000234A patent/PE20121585A1/es not_active Application Discontinuation
- 2010-08-23 BR BR112012003809A patent/BR112012003809A2/pt not_active IP Right Cessation
- 2010-08-23 EP EP10810721A patent/EP2467164A2/en not_active Withdrawn
- 2010-08-23 JP JP2012525756A patent/JP5752687B2/ja not_active Ceased
- 2010-08-23 CN CN2010800477186A patent/CN103002912A/zh active Pending
- 2010-08-23 SG SG2012011664A patent/SG178509A1/en unknown
- 2010-08-23 MX MX2012002172A patent/MX336091B/es unknown
- 2010-08-23 EA EA201200195A patent/EA201200195A1/ru unknown
- 2010-08-23 IN IN1518DEN2012 patent/IN2012DN01518A/en unknown
- 2010-08-23 KR KR1020127007280A patent/KR20120059568A/ko not_active Withdrawn
-
2012
- 2012-02-09 TN TNP2012000057A patent/TN2012000057A1/en unknown
- 2012-02-14 IL IL218097A patent/IL218097A0/en unknown
- 2012-02-15 NI NI201200027A patent/NI201200027A/es unknown
- 2012-02-17 ZA ZA2012/01195A patent/ZA201201195B/en unknown
- 2012-02-20 DO DO2012000044A patent/DOP2012000044A/es unknown
- 2012-03-05 CR CR20120108A patent/CR20120108A/es unknown
- 2012-03-12 MA MA34684A patent/MA33582B1/fr unknown
- 2012-03-21 EC ECSP12011740 patent/ECSP12011740A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011022727A3 (en) | 2013-06-27 |
| WO2011022727A2 (en) | 2011-02-24 |
| CA2771744A1 (en) | 2011-02-24 |
| BR112012003809A2 (pt) | 2019-09-24 |
| TN2012000057A1 (en) | 2013-09-19 |
| EP2467164A2 (en) | 2012-06-27 |
| KR20120059568A (ko) | 2012-06-08 |
| CN103002912A (zh) | 2013-03-27 |
| ECSP12011740A (es) | 2013-02-28 |
| MX2012002172A (es) | 2012-05-29 |
| CR20120108A (es) | 2012-06-05 |
| ZA201201195B (en) | 2015-07-29 |
| DOP2012000044A (es) | 2012-06-30 |
| AU2010284018C1 (en) | 2015-10-15 |
| MX336091B (es) | 2016-01-08 |
| AU2010284018A1 (en) | 2012-03-22 |
| JP5752687B2 (ja) | 2015-07-22 |
| EA201200195A1 (ru) | 2012-12-28 |
| AU2010284018B2 (en) | 2014-06-05 |
| SG178509A1 (en) | 2012-04-27 |
| IL218097A0 (en) | 2012-04-30 |
| JP2013506622A (ja) | 2013-02-28 |
| IN2012DN01518A (enExample) | 2015-06-05 |
| MA33582B1 (fr) | 2012-09-01 |
| PE20121585A1 (es) | 2012-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12011740A (es) | Anticuerpos contra el extodominio de erbb3 y usos de los mismos | |
| ECSP099637A (es) | Anticuerpos contra el erbb3 y los usos de los mismos | |
| CY1119154T1 (el) | Anti-vla-4 αντισωματα | |
| TR201905458T4 (tr) | Fap ve dr5 için spesifik bispesifik antikorlar, dr5 için spesifik antikorlar ve bunların kullanım yöntemleri. | |
| CY1118761T1 (el) | Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3) | |
| CR20140146A (es) | Anticuerpos anti-cd134 (ox40) y usos de los mismos | |
| CR20150493A (es) | Composiciones de amri contra el componente c5 del complemento y métodos para su uso | |
| MX369740B (es) | Anticuerpos contra claudina 18.2 útiles en el diagnóstico de cáncer. | |
| MX377710B (es) | Anticuerpos monoclonales contra bcma. | |
| CL2017002641A1 (es) | Construcciones de anticuerpos biespecíficos contra cdh3 y cd3 | |
| MX2016009954A (es) | Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd). | |
| CR20150634A (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| CO7151527A2 (es) | Anticuerpos anti-cd79 b e inmunoconjugados | |
| BR112016014966A2 (pt) | Anticorpos e fragmentos anti-vista | |
| ECSP12011583A (es) | Compuestos que modulan selectivamente el receptor CB2. | |
| WO2018151841A8 (en) | Multispecific binding molecules having specificity to dystroglycan and laminin-2 | |
| EP3370783C0 (en) | CONDENSED HEMOSTATIC CELLULOUS AGGREGATES | |
| CO7151529A2 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| CU20140073A7 (es) | Composiciones y métodos para anticuerpos que actúan sobre el factor p | |
| EP3705494A3 (en) | Antibodies against frizzled proteins and methods of use thereof | |
| CO7240413A2 (es) | Composición farmacéutica que comprende fimasartan e hidroclorotiazida | |
| CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
| EP3589320A4 (en) | ANTIBODIES UNDERGOING CYSTEINE MUTATION FOR CONJUGATION | |
| BR112017002755A2 (pt) | anticorpos direcionados contra o receptor fc gama iib e o receptor fc épsilon | |
| UY34575A (es) | Composiciones y métodos para el tratamiento de diabetes y/u obesidad |